Aims: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors treat type 2 diabetes through incretin-signaling pathways. This study compared the efficacy and safety of the glucagon-like peptide-1 receptor agonist exenatide once-weekly (Miglyol) suspension for autoinjection (QWS-AI) with the dipeptidyl peptidase-4 inhibitor sitagliptin or placebo. Materials and methods: In this open-label, multicentre study of patients with type 2 diabetes who had suboptimal glycaemic control on metformin monotherapy, 365 patients were randomized to receive exenatide 2.0 mg QWS-AI, sitagliptin 100 mg once daily or oral placebo (3:2:1 ratio). The primary endpoint was change in glycated hemoglobin (HbA1c) from baseline to 28 weeks. Results: At 28 weeks, exenatide QWS-AI significantly reduced HbA1c from baseline compared to sitagliptin (−1.13% vs −0.75% [baseline values, 8.42% and 8.50%, respectively]; P =.02) and placebo (−0.40% [baseline value, 8.50%]; P =.001). More exenatide QWS-AI-treated patients achieved HbA1c <7.0% than did sitagliptin- or placebo-treated patients (43.1% vs 32.0% and 24.6%; both P
CITATION STYLE
Gadde, K. M., Vetter, M. L., Iqbal, N., Hardy, E., & Öhman, P. (2017). Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study. Diabetes, Obesity and Metabolism, 19(7), 979–988. https://doi.org/10.1111/dom.12908
Mendeley helps you to discover research relevant for your work.